ArticleJournal of translational medicine2026
Targeting the FGF19/FGFR4 positive feedback loop to disrupt ERK-mediated tumor progression in head and neck cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHead and neck cancer (HNC) is a biologically heterogeneous malignancy with limited actionable therapeutic targets. The fibroblast growth factor receptor (FGFR) family comprises receptor tyrosine kinases implicated in tumor progression; however, their specific roles in HNC remain incompletely defined.
methodsGenomic alterations, transcriptomic profiles, and clinical relevance of FGFR1–FGFR4 were assessed in the TCGA/HNC cohort and in an independent validation set. Gain- and loss-of-function assays were performed to examine FGFR4 in cell motility, clonogenicity, and chemoresistance. Bioinformatic analyses and pharmacological perturbations were used to delineate FGFR4 regulatory mechanisms.
resultsAmong FGFR family members, FGFR4 was consistently overexpressed in HNC tissues and associated with poor prognosis. Functionally, FGFR4 promoted migration, invasion, and clonogenicity without affecting proliferation. Mechanistically, FGFR4 induced ERK activation, which upregulated RUNX3 and subsequently increased MMP2 expression. Pharmacological ERK inhibition suppressed RUNX3-MMP2 axis and attenuated migration and invasion in FGFR4-overexpressing cells. FGFR4 overexpression also conferred resistance to cisplatin, 5-fluorouracil, and docetaxel. Trametinib partially restored chemosensitivity in vitro and markedly enhanced cisplatin efficacy in vivo. Additionally, ERK activation increased both FGFR4 and FGF19 expressions, whereas ERK inhibition suppressed FGF19 and FGFR4 upregulation observed in HNC cells. Moreover, exogenous FGF19 further induced FGFR4 expression and ERK activation, consistent with a self-reinforcing FGF19–FGFR4–ERK feedback loop.
conclusionFGFR4 functions as an oncogenic driver in HNC, promoting tumor progression through the ERK–RUNX3–MMP2 axis and mediating chemoresistance via FGFR4–ERK signaling. The ERK-dependent induction of FGF19 and FGFR4 establishes a positive feedback circuit that sustains oncogenic activation. Targeting the FGF19/FGFR4 axis, particularly when combined with MEK/ERK inhibitors, represents a promising strategy to overcome resistance in HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.